3月25日 - ** 在法国杂志《Lettre》报导J&J JNJ.N正在考虑收购这家法国纳米医药公司之后，Nanobiotix NANOB.PA的股价上涨了约9%。
** 两家公司都没有立即回应路透的置评请求
** Kempen生命科学研究公司的分析师在一份报告中称，鉴于两家公司目前的合作关系，J&J拥有实验性癌症治疗药物NBTXR3的独家许可，现阶段不太可能进行收购。
** 截至周二收盘，Nanobiotix公司的股价年累计上涨了约30%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.